

Hyperfine, Inc. (HYPR)

Nasdaq; healthcare; SIC 3845, Electromedical & Electrotherapeutic Apparatus; CIK 0001833769

Hyperfine, Inc.
HYPR; healthcare

Grade

D/E

on the D/E boundary of 371 graded peers
percentile 81.4; sampling error 2.5 points; lower is stronger

Rank

302 of 371

Profitability

D

percentile 68.5

Solvency

C

percentile 56.7

Growth and financing

C/D

percentile 57.5

Reliability

0.83 AUC
filers with \$12.5M to \$120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025

Peer failure rate

1.07% a year
Item 1.03 bankruptcies, same asset band, 2012 to 2025

Size band

\$12.5M to \$120M assets
total assets \$55.3M

Standard universe

inside
revenue above \$1M and assets above \$10M

Warnings

none active
not computable: dilution, distress, fortress balance sheet

Inputs computable

7 of 14

Graded from

filings received through Mar 18, 2026
205 days before the rescan; latest periodic filing 10-Q received Aug 6, 2026

Last close

\$0.94
2026-10-08; market equity \$0

Price used in grade


None



D/E, the sloth
on the D/E boundary of its sector; letters are fifths of the 371 graded peers

Share price, twelve months to the rescan

split-adjusted close; the letter is fixed at the rescan that set it



Rescans on file: D/E from Mar 21, 2026, E from Apr 21, 2026, D/E from May 21, 2026

Letter at every rescan

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only


A

B

C

D

E



Business, in the company's words

opening of Item 1 of the 10-K received Mar 18, 2026

We are an innovative health technology business with a mission to revolutionize patient care globally through accessible, affordable, clinically relevant artificial intelligence ("AI")-powered portable ultra-low-field ("ULF") magnetic resonance ("MR") brain imaging. Our Swoop® Portable MR Imaging® System ("Swoop® system") produces high-quality images at a significantly lower magnetic field strength than conventional magnetic resonance imaging ("MRI") scanners.

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Assay HYPR, as of Oct 9, 2026, page 1


The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 68.5						
Gross profitability		12.2%	32.2%	72.8	372	2025-12-31
Return on invested capital		not computable	9.3%			one or more required annual facts are missing
Accruals ratio		(13.4%)	(6.6%)	33.1	811	2025-12-31
Gross margin stability, five years		48.2 pts	2.8 pts	99.6	243	2025-12-31
Solvency, sleeve percentile 56.7						
Twelve-month failure probability		not computable	0.07%			liabilities and a nearby cover-page share count are required at 2026-06-30
Altman Z double-prime		(16.31)	(0.31)	71.0	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			one or more required annual facts are missing
Interest coverage		not computable	(4.51x)			one or more required annual facts are missing
Current ratio		4.34x	2.96x	42.4	839	2025-12-31
Growth and financing, sleeve percentile 57.5						
Revenue growth, three-year compound		25.8%	10.0%	25.8	415	2025-12-31
Free cash flow growth, three-year compound		not computable	10.9%			current FCF must be positive and base FCF must exceed \$100,000
Reinvestment rate		not computable	37.1%			NOPAT must exceed \$100,000
Asset growth, three years		(25.6%)	2.1%	89.2	704	2025-12-31
Net share issuance, one year		not computable	2.5%			two annual share counts are required; found 0

Among 371 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
297	Champions Oncology, Inc. (CSBR)	80.0	D/E	
298	Voyager Therapeutics, Inc. (VYGR)	80.3	D/E	short runway
299	Lucid Diagnostics Inc. (LUCD)	80.5	D/E	dilution
300	Merck & Co., Inc. (MRK)	80.8	D/E	
301	Lexicon Pharmaceuticals, Inc. (LXRX)	81.1	D/E	fortress
				balance sheet
302	Hyperfine, Inc. (HYPR) <	81.4	D/E	
303	Surgery Partners, Inc. (SGRY)	81.6	D/E	late filer
304	Personalis, Inc. (PSNL)	81.9	D/E	
305	Accuray Inc. (ARAY)	82.2	D/E	late filer
306	Moderna, Inc. (MRNA)	82.4	D/E	
307	Stereotaxis, Inc. (STXS)	82.7	E	

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(43.2%)	8.0%	17
Distance from 52-week high	(57.3%)	(31.4%)	19
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	not computable	(1.0%)	
Book value to price	not computable	0.28	
Sales to price	not computable	0.31	
Composite equity issuance, five years	not computable	20.3%	
Relative strength against the sector, log excess return	(0.78)	(0.14)	17

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	pass
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	\$43.5M
Operating cash flow, four quarters	-\$27.1M
Months of runway	19.3
Days since last periodic filing	64 (10-Q received Aug 6, 2026)
Median daily dollar volume, 63 sessions	\$466,162

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	\$6.8M	2025-12-31	2026-03-18	10-K	0001193125-26-114044
2	assets	us-gaap:Assets	\$55.3M	2025-12-31	2026-03-18	10-K	0001193125-26-114044
3	net income	us-gaap:NetIncomeLoss	-\$35.6M	2025-12-31	2026-03-18	10-K	0001193125-26-114044
4	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$27.9M	2025-12-31	2026-03-18	10-K	0001193125-26-114044
5	assets	us-gaap:Assets	\$58.9M	2024-12-31	2026-03-18	10-K	0001193125-26-114044
6	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$13.6M	2025-12-31	2026-03-18	10-K	0001193125-26-114044
7	gross profit	us-gaap:GrossProfit	\$5.9M	2024-12-31	2026-03-18	10-K	0001193125-26-114044
8	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$12.9M	2024-12-31	2026-03-18	10-K	0001193125-26-114044
9	gross profit	us-gaap:GrossProfit	\$4.8M	2023-12-31	2025-03-17	10-K	0000950170-25-040281
10	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$11.0M	2023-12-31	2025-03-17	10-K	0000950170-25-040281
11	gross profit	us-gaap:GrossProfit	\$907,000	2022-12-31	2024-03-22	10-K	0000950170-24-035343
12	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$6.8M	2022-12-31	2024-03-22	10-K	0000950170-24-035343
13	gross profit	us-gaap:GrossProfit	-\$1.2M	2021-12-31	2023-03-22	10-K	0000950170-23-009159
14	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$1.5M	2021-12-31	2023-03-22	10-K	0000950170-23-009159
15	current assets	us-gaap:AssetsCurrent	\$50.9M	2025-12-31	2026-03-18	10-K	0001193125-26-114044
16	current liabilities	us-gaap:LiabilitiesCurrent	\$11.7M	2025-12-31	2026-03-18	10-K	0001193125-26-114044
17	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$330.0M	2025-12-31	2026-03-18	10-K	0001193125-26-114044
18	operating income	us-gaap:OperatingIncomeLoss	-\$37.1M	2025-12-31	2026-03-18	10-K	0001193125-26-114044
19	book equity	us-gaap:StockholdersEquity	\$41.0M	2025-12-31	2026-03-18	10-K	0001193125-26-114044
20	liabilities	us-gaap:Liabilities	\$14.3M	2025-12-31	2026-03-18	10-K	0001193125-26-114044
21	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$1.2M	2025-12-31	2026-03-18	10-K	0001193125-26-114044
22	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$38.8M	2024-12-31	2026-03-18	10-K	0001193125-26-114044
23	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$383,000	2024-12-31	2026-03-18	10-K	0001193125-26-114044
24	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$41.8M	2023-12-31	2025-03-17	10-K	0000950170-25-040281
25	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$804,000	2023-12-31	2025-03-17	10-K	0000950170-25-040281
26	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$72.3M	2022-12-31	2024-03-22	10-K	0000950170-24-035343
27	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$585,000	2022-12-31	2024-03-22	10-K	0000950170-24-035343
28	depreciation amortization	us-gaap:Depreciation	\$1.1M	2025-12-31	2026-03-18	10-K	0001193125-26-114044
29	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraord	\$35.6M	2025-12-31	2026-03-18	10-K	0001193125-26-114044
30	income tax	us-gaap:IncomeTaxExpenseBenefit	\$0	2025-12-31	2026-03-18	10-K	0001193125-26-114044
31	current assets	us-gaap:AssetsCurrent	\$53.7M	2024-12-31	2026-03-18	10-K	0001193125-26-114044
32	current liabilities	us-gaap:LiabilitiesCurrent	\$8.7M	2024-12-31	2026-03-18	10-K	0001193125-26-114044
33	assets	us-gaap:Assets	\$94.2M	2023-12-31	2025-03-17	10-K	0000950170-25-040281
34	assets	us-gaap:Assets	\$134.1M	2022-12-31	2024-03-22	10-K	0000950170-24-035343